OAC
FBRX icon

OMERS Administration Corp’s Forte Biosciences FBRX Stock Holding History

OMERS Administration Corp’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-15,600
Closed -$425K – 1123
2025
Q4 		$425K Buy
+15,600
New +$274K ﹤0.01% 718

Other funds holding FBRX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return

OMERS Administration Corp's FBRX Position: Q1 2026 in Review

OMERS Administration Corp sold out of Forte Biosciences (FBRX) in Q1 2026, closing a stake of 15,600 shares — an estimated $425K sold.

OMERS Administration Corp first reported a position in FBRX in Q4 2025 and held it in 1 quarter. The position peaked at $425K in Q4 2025. 68 funds tracked by Wall St. Rank hold FBRX as of Q1 2026.

  • OMERS Administration Corp reported no remaining Forte Biosciences position as of Q1 2026 after selling out during the quarter.
  • OMERS Administration Corp sold 15,600 Forte Biosciences shares in Q1 2026, an estimated $425K.
  • OMERS Administration Corp first reported a position in Forte Biosciences in Q4 2025 and held it in 1 quarter.
  • OMERS Administration Corp's Forte Biosciences position peaked at $425K in Q4 2025.
  • 68 funds tracked by Wall St. Rank held Forte Biosciences as of Q1 2026.

Based on OMERS Administration Corp's 13F filing for Q1 2026, filed 15 May 2026.